Ipsen | Sustainability Performance
Develops and markets pharmaceuticals for various medical conditions, including oncology and rare diseases.
1929
France
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#93
Overallⓘ#8
in Franceⓘ#3
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Laggard
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
3.5
B/M 13.9
24.8
B/M 111.2
19.6
B/M 65.5
Powered by illuminem and GIST Impact
Controversy level
- Ipsen has faced multiple US and EU pharmaceutical regulatory enforcement actions over Somatuline marketing practices and the historic 2014 USD 13.5 million Office of Inspector General compliance settlement at the US Tarceva subsidiary.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.